medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2021-1-270-275medsovet-6058Research ArticleШКОЛА ПЕДИАТРАPEDIATRICIAN SCHOOLПротивовирусный растительный препарат как актуальное средство лечения респираторных вирусных инфекций у взрослых и детейAntiviral plant preparation as a topical treatment for respiratory viral infections in adults and childrenhttps://orcid.org/0000-0002-2178-0451ГригорянС. С.GrigoryanSeda S.

Григорян Седа Суреновна, д.м.н., профессор, лауреат премии правительства РФ в области науки и техники, вирусолог-иммунолог, ведущий научный сотрудник

123098, Москва, ул. Гамалеи, д. 18

Seda S. Grigoryan, Dr. of Sci. (Med.), Professor, Winner of the Russian Federation Government Prize in Science and Technology, virolo  gistimmunologist, leading researcher

18, Gamaleya St., Moscow, 123098

grig-seda@yandex.ruhttps://orcid.org/0000-0002-5024-6135ГаращенкоТ. И.GarashchenkoTatiana I.

Гаращенко Татьяна Ильинична, д.м.н. профессор, ученый секретарь,  профессор кафедры оториноларингологии

123182,  Москва, Волоколамское шоссе, д. 30, корп. 2 117997, Москва, ул. Островитянова, д. 1

Tatiana I. Garashchenko, Dr. of Sci. (Med.), Professor, Scientific Secretary of Scientific and Clinical Center of Otorhinolaryngology; Professor of the Department of Otorhinolaryngology Faculty of Additional Professional Education

30, Bldg. 2, Volokolamskoe Shosse, Moscow, 123182

1, Ostrovityanov St., Moscow, 117997

9040100@mail.ruНациональный исследовательский центр эпидемиологии и микробиологии им. Н.Ф. ГамалеиРоссияGamaleya National Research Center for Epidemiology and MicrobiologyRussian FederationНациональный медицинский исследовательский центр оториноларингологии Федерального медико-биологического агентства; Российский национальный исследовательский медицинский университет им. Н.И. ПироговаРоссияScientific and Clinical Center of Otorhinolaryngology of the Federal Medico-Biological Agency of the Russian Federation; Pirogov Russian National Research Medical UniversityRussian Federation20212103202101270275Copyright © Григорян С.С., Гаращенко Т.И., 20212021Григорян С.С., Гаращенко Т.И.Grigoryan S.S., Garashchenko T.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/6058

В среднем из 57 млн (в настоящее время и более) ежегодных смертей в мире более 25% напрямую вызваны инфекцион-ными заболеваниями. Из них более 90% являются эпидемиями респираторных вирусных заболеваний, включая различные варианты гриппа и новую коронавирусную инфекцию, а также ВИЧ/СПИД, желудочно-кишечные заболевания, туберкулез, малярию, корь и возникающие на их фоне бактериальные осложнения. Особую значимость в профилактике и лечении респираторных вирусных инфекций в группах риска имеет место применение растительных препаратов, отличающихся безопасностью, отсутствием нежелательных побочных эффектов и хорошо изученных в схемах лечения заболеваний, передающихся воздушно-капельным путем. В статье уделено внимание противовирусному препарату на основе жидкого экстракта корней южноафриканской герани Pilargonium sidoides(EPs ® 7630), соответству-ющему данным требованиям. Противовирусная активность препарата исследована и установлена на модели различных штаммов вируса гриппа и других респираторных вирусных инфекций в культуре клеток MDCK, Vero, А549, L 929 и фибробластов эмбриона человека, а также in vivo в ряде рандомизированных клинических испытаний у детей и взрослых при острых респираторных инфекциях. Кроме этого, доказано противовирусное действие EPs ®  7630 на репликацию широкого круга респираторных вирусов, включая вирус гриппа A (H1N1, H3N2, H5N1), респираторно-синцитиальный вирус (RSV), аденовирус, вирус парагриппа, риновирус, вирус Коксаки и один из коронавирусов человека. Приведен обзор рандомизированных многоцентровых плацебо-контролируемых двойных слепых клинических исследований, проведенных в разные годы в различных странах по эффективности EPs ® 7630.  Учитывая результаты исследований эффективности в профилактике и лечении вирусных респираторных заболеваний, проведенных в разные годы, препарат EPs ®  7630 заслуженно включен в международные и российские рекомендации. Он предпочтителен как универсальное средство для противовирусной терапии и профилактики широкого круга респираторных заболеваний детей и взрослых.

On average, of the 57 million (currently more) annual deaths worldwide, more than 25% are directly related to infectious diseases. Of these, more than 90% are epidemics of respiratory viral diseases, including variants of influenza and a new coronavirus infection, as well as HIV/AIDS, gastrointestinal diseases, tuberculosis, malaria, measles, and associated bacterial complications. Of particular importance in the prevention and treatment of respiratory viral infections in at-risk groups is the use of plant preparations notable for their safety, absence of undesirable side effects and well studied in the treatment regimens of airborne diseases. The article focuses on an antiviral drug based on a liquid root extract of South African geranium Pilargonium sidoides (EPs® 7630) that meets these requirements. Antiviral activity of the drug was investigated and established in the model of different strains of influenza virus and other respiratory viral infections in cell cultures MDCK, Vero, A549, L 929 and human embryonic fibroblasts, as well as in vivo in a number of randomized clinical trials in children and adults with acute respiratory infections. In addition, EPs® 7630 has proven antiviral effect on the replication of a wide range of respiratory viruses, including influenza A virus (H1N1, H3N2, H5N1), respiratory syncytial virus (RSV), adenovirus, parainfluenza virus, rhinovirus, coxsackievirus and one of human coronaviruses. A review of randomized multicenter placebo-controlled double-blind clinical trials conducted in different years in different countries on the effectiveness of EPs® 7630 is presented. Taking into account the results of efficacy trials in the prevention and treatment of viral respiratory diseases conducted in different years, EPs® 7630 is deservedly included in international and Russian recommendations. It is preferred as a universal agent for antiviral therapy and prevention of a wide range of respiratory diseases in children and adults.

респираторные вирусные заболеванияCOVID-19профилактикалечениеEPs® 7630respiratory viral diseasesCOVID-19preventiontreatmentEPs® 7630ReferencesBrendler T., van Wyk B.E. A historical, scientific and commercial perspective on the medical use of Pelargonium sidoides (Geraniaceae). J Ethnopharmacol. 2008;119(3):420–433. doi: 10.1016/j.jep.2008.07.037.Brendler T., van Wyk B.E. A historical, scientific and commercial perspective on the medical use of Pelargonium sidoides (Geraniaceae). J Ethnopharmacol. 2008;119(3):420–433. doi: 10.1016/j.jep.2008.07.037.Conrad A., Kolodziej H., Schulz V. Pelargonium sidoides-extract (EPs ® 7630): registration confirms efficacy and safety. Wien Med Wochenschr. 2007;157(13–14):331–336. (In German) doi: 10.1007/s10354-007-0434-6.Conrad A., Kolodziej H., Schulz V. Pelargonium sidoides-extract (EPs ® 7630): registration confirms efficacy and safety. Wien Med Wochenschr. 2007;157(13–14):331–336. (In German) doi: 10.1007/s10354-007-0434-6.Haidvogl M., Heger M. Treatment effect and safety of Eps 7630-solution in acute bronchitis in childhood: Report of a multicentre observational study. Phytomedicine. 2007;14(6 Suppl.):60–64. doi: 10.1016/j.phymed.2006.11.014.Haidvogl M., Heger M. Treatment effect and safety of Eps 7630-solution in acute bronchitis in childhood: Report of a multicentre observational study. Phytomedicine. 2007;14(6 Suppl.):60–64. doi: 10.1016/j.phymed.2006.11.014.Matthys H., Funk P. EPs 7630 improves acute bronchitis symptoms and shortens time to remission. Results of a randomized, double-blind, placebo-controlled, multicentre trial. Planta Med. 2008;74(6):686–692. doi: 10.1055/s-2008-1074519.Matthys H., Funk P. EPs 7630 improves acute bronchitis symptoms and shortens time to remission. Results of a randomized, double-blind, placebo-controlled, multicentre trial. Planta Med. 2008;74(6):686–692. doi: 10.1055/s-2008-1074519.Kamin W., Maydannik V.G., Malek F.A., Kieser M. Efficacy and tolerability of EPs 7630 in children and adolescents with acute bronchitis – a randomized, double-blind, placebo-controlled multicenter trial with a herbal drug preparation from Pelargonium sidoides roots. Int J Clin Pharmacol Ther. 2010;48(3):184–191. doi: 10.5414/cpp48184.Kamin W., Maydannik V.G., Malek F.A., Kieser M. Efficacy and tolerability of EPs 7630 in children and adolescents with acute bronchitis – a randomized, double-blind, placebo-controlled multicenter trial with a herbal drug preparation from Pelargonium sidoides roots. Int J Clin Pharmacol Ther. 2010;48(3):184–191. doi: 10.5414/cpp48184.Мatthys H., Heger M. Treatment of acute bronchitis with liquid herbal drug preparation from Pelargonium sidoides (Eps 7630): A randomized, double-blind, placebo-controlled multicentre study. Curr Med Res Opin. 2007;23(2):323–331. doi: 10.1185/030079906X167318.Мatthys H., Heger M. Treatment of acute bronchitis with liquid herbal drug preparation from Pelargonium sidoides (Eps 7630): A randomized, double-blind, placebo-controlled multicentre study. Curr Med Res Opin. 2007;23(2):323–331. doi: 10.1185/030079906X167318.Bachert C., Schapowal A., Funk P., Keiser M. Treatment of acute rhinosinusitis with the preparation from Pelargonium sidodies EPs 7630: A randomized, double-blind, placebo-controlled trial. Rhinology. 2009;47(1):51–55. Available at: https://pubmed.ncbi.nlm.nih.gov/19382496.Bachert C., Schapowal A., Funk P., Keiser M. Treatment of acute rhinosinusitis with the preparation from Pelargonium sidodies EPs 7630: A randomized, double-blind, placebo-controlled trial. Rhinology. 2009;47(1):51–55. Available at: https://pubmed.ncbi.nlm.nih.gov/19382496.Чучалин А.Г., Берман Б., Лемахер В. Лечение острого бронхита у взрослых экстрактом пеларгонии сидовидной (Pelargonium sidoides; (EPs7630): рандомизированное двойное-слепое плацебо контролируемое исследование. Пульмонология. 2007;(6):49–55. doi: 10.18093/0869-0189-2007-0-6-49-55.Chuchalin A.G., Berman B., Lemakher V. Treatment of acute bronchitis in adults with extract of Pelargonium Sidoides: a randomised, double-blind, placebo controlled trial. Pulmonologiya = Russian Pulmonology. 2007;(6):49–55. (In Russ.) doi: 10.18093/0869-0189-2007-0-6-49-55.Григорян С.С., Гаращенко Т.И. Противовирусное действие растительного препарата на продукцию вируса гриппа в культуре фибробластов легких эмбриона человека. Медицинский совет. 2020;(18):65–70. doi: 10.21518/2079-701X-2020-18-65-70.Grigoryan S.S., Garashchenko T.I. Antiviral effect of plant-based drug on flu virus production in human fetal lung fibroblasts culture. Meditsinskiy sovet = Medical Council. 2020;(18):65–70. (In Russ.) doi: 10.21518/2079-701X-2020-18-65-70.Michaelis M., Doerr H.W., Cinatl J. Jr. Investigation of the influence of EPs® 7630, a herbal drug preparation from Pelargonium sidoiges, on replication of a broаd panel of respiratory viruses. Phitomedicine. 2011;18(5):384–386. doi: 10.1016/j.phymed.2010.09.008.Michaelis M., Doerr H.W., Cinatl J. Jr. Investigation of the influence of EPs® 7630, a herbal drug preparation from Pelargonium sidoiges, on replication of a broаd panel of respiratory viruses. Phitomedicine. 2011;18(5):384–386. doi: 10.1016/j.phymed.2010.09.008.Theisen L.L., Muller C.P. EPs 7630 (Umckaloado), an extract from Pelargonium sidoides roots, exerts anti-influenza virus activity in vitro and in vivo. Antiviral Res. 2012;94(2):147–156. doi: 10.1016/j.antiviral.2012.03.006.Theisen L.L., Muller C.P. EPs 7630 (Umckaloado), an extract from Pelargonium sidoides roots, exerts anti-influenza virus activity in vitro and in vivo. Antiviral Res. 2012;94(2):147–156. doi: 10.1016/j.antiviral.2012.03.006.Kolodziej Н. Antimicrobial, Antiviral and Immunomodulatory Activity Studies of Pelargonium sidoides (EPs® 7630) in the Context of Health Promotion. Pharmaceuticals (Basel). 2011;4(10):1295–1314. doi: 10.3390/ph4101295.Kolodziej Н. Antimicrobial, Antiviral and Immunomodulatory Activity Studies of Pelargonium sidoides (EPs ® 7630) in the Context of Health Promotion. Pharmaceuticals (Basel). 2011;4(10):1295–1314. doi: 10.3390/ph4101295.Witte K., Koch E., Volk H.D., Wolk K., Sabat R. The Pelargonium sidoides Extract EPs7630 Drives the Innate Immune Defense by Activating Selected MAP Kinase Pathways in Human Monocytes. PLoS One. 2015;10(9):e0138075. doi: 10.1371/journal.pone.0138075.Witte K., Koch E., Volk H.D., Wolk K., Sabat R. The Pelargonium sidoides Extract EPs7630 Drives the Innate Immune Defense by Activating Selected MAP Kinase Pathways in Human Monocytes. PLoS One. 2015;10(9):e0138075. doi: 10.1371/journal.pone.0138075.Neugebauer P., Mickenhagen A., Siefer O., Walger M. A new approach to pharmacological effects on ciliary beat frequency in cell cultures – exemplary measurements under Pelargonium sidoidesextract (EPs 7630). Phytomedicine. 2005;12(1–2):46–51. doi: 10.1016/j.phymed.2003.11.005.Neugebauer P., Mickenhagen A., Siefer O., Walger M. A new approach to pharmacological effects on ciliary beat frequency in cell cultures – exemplary measurements under Pelargonium sidoidesextract (EPs 7630). Phytomedicine. 2005;12(1–2):46–51. doi: 10.1016/j.phymed.2003.11.005.Matthys H., Eisebitt R., Seith B., Heger M. Efficacy and safety of an extract of Pelargonium sidoides (EPs 7630) in adults with acute bronchitis. A randomized, double-blind, placebo-controlled trial. Phytomedicine. 2003;10(Suppl. 4):7–17. doi: 10.1078/1433-187x-00308.Matthys H., Eisebitt R., Seith B., Heger M. Efficacy and safety of an extract of Pelargonium sidoides (EPs 7630) in adults with acute bronchitis. A randomized, double-blind, placebo-controlled trial. Phytomedicine. 2003;10(Suppl. 4):7–17. doi: 10.1078/1433-187x-00308.Matthys H., Heger M. EP 7630-solution – an effective therapeutic option in acute and exacerbating bronchitis. Phytomedicine. 2007;14(6 Suppl.):65–68. doi: 10.1016/j.phymed.2006.11.017.Matthys H., Heger M. EP 7630-solution – an effective therapeutic option in acute and exacerbating bronchitis. Phytomedicine. 2007;14(6 Suppl.):65–68. doi: 10.1016/j.phymed.2006.11.017.Matthys H., Kamin W., Funk P., Heger M. Pelargonium sidoides preparation (EPs7630) in the treatment of acute bronchitis in adults and children. Phytomedicine. 2007;14(6 Suppl.):69–73. doi: 10.1016/j.phymed.2006.11.015.Matthys H., Kamin W., Funk P., Heger M. Pelargonium sidoides preparation (EPs7630) in the treatment of acute bronchitis in adults and children. Phytomedicine. 2007;14(6 Suppl.):69–73. doi: 10.1016/j.phymed.2006.11.015.Kamin W., Ilyenko L.I., Malek F.A., Kieser M. Treatment of acute bronchitis with EPs 7630: randomized, controlled trial in children and adolescents. Pediatr Int. 2012;54(2):219–226. doi: 10.1111/j. 1442-200X.2012.03598.xKamin W., Ilyenko L.I., Malek F.A., Kieser M. Treatment of acute bronchitis with EPs 7630: randomized, controlled trial in children and adolescents. Pediatr Int. 2012;54(2):219–226. doi: 10.1111/j. 1442-200X.2012.03598.xKamin W., Funk P., Seifert G., Zimmermann A., Lehmacher W. EPs7630 is effective and safe in children under 6 years with a cuter espiratory tract infections: clinical studies revisited. Curr Med Res Opin. 2018;34(3):475–485. doi: 10.1080/03007995.2017.1402754.Kamin W., Funk P., Seifert G., Zimmermann A., Lehmacher W. EPs7630 is effective and safe in children under 6 years with a cuter espiratory tract infections: clinical studies revisited. Curr Med Res Opin. 2018;34(3):475–485. doi: 10.1080/03007995.2017.1402754.Matthys H., Pliskevich D.A., Bondarchuk O.M., Malek F.A., Tribanek M., Kieser M. Randomised, double-blind, placebo-controlled trial of EPs7630 in adults with COPD. Respir Med. 2013;107(5):691–701. doi: 10.1016/j.rmed.2013.02.011.Matthys H., Pliskevich D.A., Bondarchuk O.M., Malek F.A., Tribanek M., Kieser M. Randomised, double-blind, placebo-controlled trial of EPs7630 in adults with COPD. Respir Med. 2013;107(5):691–701. doi: 10.1016/j.rmed.2013.02.011.Wilkinson T.M.A., Aris E., Bourne S., Clarke S.C., Peeters M., Pascal T.G. et al. A prospective, observational cohort study of the seasonal dynamics of airway pathogens in the aetiology of exacerbations in COPD. Thorax. 2017;72(10):919–927. doi: 10.1136/thoraxjnl-2016-209023.Wilkinson T.M.A., Aris E., Bourne S., Clarke S.C., Peeters M., Pascal T.G. et al. A prospective, observational cohort study of the seasonal dynamics of airway pathogens in the aetiology of exacerbations in COPD. Thorax. 2017;72(10):919–927. doi: 10.1136/thoraxjnl-2016-209023.Ritchie A.I., Farne H.A., Singanayagam A., Jackson D.J., Mallia P., Johnston S.L. Pathogenesis of Viral Infection in Exacerbations of Airway Disease. Ann Am Thorac Soc. 2015;12(2 Suppl.):115–132. doi: 10.1513/AnnalsATS.201503-151AW.Ritchie A.I., Farne H.A., Singanayagam A., Jackson D.J., Mallia P., Johnston S.L. Pathogenesis of Viral Infection in Exacerbations of Airway Disease. Ann Am Thorac Soc. 2015;12(2 Suppl.):115–132. doi: 10.1513/AnnalsATS.201503-151AW.Thibaut H.J., Lacroix C., De Palma A.M., Franco D., Decramer M., Neyts J. Toward antiviral therapy/prophy-laxis for rhinovirus-induced exacerbations of chronic obstructive pulmonary disease: challenges, opportunities, and strategies. Rev Med Virol. 2016;26(1):21–33. doi: 10.1002/rmv.1856.Thibaut H.J., Lacroix C., De Palma A.M., Franco D., Decramer M., Neyts J. Toward antiviral therapy/prophy-laxis for rhinovirus-induced exacerbations of chronic obstructive pulmonary disease: challenges, opportunities, and strategies. Rev Med Virol. 2016;26(1):21–33. doi: 10.1002/rmv.1856.Tahan F., Yaman M. Can the Pelargonium sidoides root extract EPs7630 prevent asthma attacks during viral infections of the upper respiratory tract in children? Phytomedicine. 2013;20(2):148–150. doi: 10.1016/j.phymed.2012.09.022.Tahan F., Yaman M. Can the Pelargonium sidoides root extract EPs7630 prevent asthma attacks during viral infections of the upper respiratory tract in children? Phytomedicine. 2013;20(2):148–150. doi: 10.1016/j.phymed.2012.09.022.Looi K., Buckley A.G., Rigby P.J., Garratt L.W., Iosifidis T., Zosky G.R. et al. Effects of human rhinovirus on epithelial barrier integrity and function in children with asthma. Clin Exp Allergy. 2018;48(5):513–524. doi: 10.1111/cea.13097.Looi K., Buckley A.G., Rigby P.J., Garratt L.W., Iosifidis T., Zosky G.R. et al. Effects of human rhinovirus on epithelial barrier integrity and function in children with asthma. Clin Exp Allergy. 2018;48(5):513–524. doi: 10.1111/cea.13097.Careddu D., Pettenazzo A. Pelargonium sidoides extract EPs7630: a view of its clinical efficacy and safety for treating acute respiratory tract infections in children. Int J Gen Med. 2018;11:91–98. doi: 10.2147/IJGM.S154198.Careddu D., Pettenazzo A. Pelargonium sidoides extract EPs7630: a view of its clinical efficacy and safety for treating acute respiratory tract infections in children. Int J Gen Med. 2018;11:91–98. doi: 10.2147/IJGM.S154198.Roth M., Fang M., Stolz D., Tamm M. Pelargonium radix extract EPs7630 reduces rhinovirus infection through modulation of viral binding proteins on human bronchial epithelial cells. PLoS One. 2019;14(2):e0210702. doi: 10.1371/journal.pone.0210702.Roth M., Fang M., Stolz D., Tamm M. Pelargonium radix extract EPs7630 reduces rhinovirus infection through modulation of viral binding proteins on human bronchial epithelial cells. PLoS One. 2019;14(2):e0210702. doi: 10.1371/journal.pone.0210702.Bereznoy V.V., Riley D.S., Wassmer G., Heger M. Efficacy of extract of Pelargonium sidoides in children with a cutenon-group A beta-hemolytic streptococcus tonsillopharyngitis: a randomized, double-blind, placebocontrolled trial. Altern Ther Health Med. 2003;9(5):68–79. Available at: https://pubmed.ncbi.nlm.nih.gov/14526713.Bereznoy V.V., Riley D.S., Wassmer G., Heger M. Efficacy of extract of Pelargonium sidoides in children with a cutenon-group A beta-hemolytic streptococcus tonsillopharyngitis: a randomized, double-blind, placebocontrolled trial. Altern Ther Health Med. 2003;9(5):68–79. Available at: https://pubmed.ncbi.nlm.nih.gov/14526713.Kirk K.M., Garbes Netto P.G. Post-marketing surveillance of Pelargonium sidoides for treatment of presumably viral acute community acquired tonsillopharyngitis. Rev Panam Infectol. 2007;9:15–24.Kirk K.M., Garbes Netto P.G. Post-marketing surveillance of Pelargonium sidoides for treatment of presumably viral acute community acquired tonsillopharyngitis. Rev Panam Infectol. 2007;9:15–24.Lizogub V.G., Riley D.S., Heger M. Efficacy of a Pelargonium sidoides preparation in patients with the common cold: a randomized, double-blind, placebo-controlled clinical trial. Explore (NY). 2007;3(6):573–584. doi: 10.1016/j.explore.2007.09.004.Lizogub V.G., Riley D.S., Heger M. Efficacy of a Pelargonium sidoides preparation in patients with the common cold: a randomized, double-blind, placebo-controlled clinical trial. Explore (NY). 2007;3(6):573–584. doi: 10.1016/j.explore.2007.09.004.Schapowal A., Dobos G., Cramer H., Ong K.C., Adler M., Zimmermann A. et al. Results of Meta-Analysis 2019. Treatment of signs and symptoms of the common cold using EPs 7630 – results of a meta-analys. Heliyon. 2019;5(11):e02904. doi: 10.1016/j.heliyon.2019.e02904.Schapowal A., Dobos G., Cramer H., Ong K.C., Adler M., Zimmermann A. et al. Results of Meta-Analysis 2019. Treatment of signs and symptoms of the common cold using EPs 7630 – results of a meta-analys. Heliyon. 2019;5(11):e02904. doi: 10.1016/j.heliyon.2019.e02904.Silveira D., Prieto-Garcia J.M., Boylan F., Estrada O., Fonseca-Bazzo Y.M., Jamal C.M. et al. COVID-19: Is There Evidence for the Use of Herbal Medicines as Adjuvant Symptomatic Therapy? Front Pharmacol. 2020;11:581840. doi: 10.3389/fphar.2020.581840.Silveira D., Prieto-Garcia J.M., Boylan F., Estrada O., Fonseca-Bazzo Y.M., Jamal C.M. et al. COVID-19: Is There Evidence for the Use of Herbal Medicines as Adjuvant Symptomatic Therapy? Front Pharmacol. 2020;11:581840. doi: 10.3389/fphar.2020.581840.Fokkens W.J., Lund V.J., Mullol J., Bachert C., Alobid I., Baroody F. European Position Paper on Rhinosinusitis and Nasal Polyps 2012. Available at: https://epos2020.com/Documents/EPOS2012.pdf.Fokkens W.J., Lund V.J., Mullol J., Bachert C., Alobid I., Baroody F. European Position Paper on Rhinosinusitis and Nasal Polyps 2012.Available at: https://epos2020.com/Documents/EPOS2012.pdf.Fashner U., Ericson K., Werner S. Treatment of the Common Cold in Children and Adults. Am Fam Physician. 2012;86(2):153–159. Available at: https://pubmed.ncbi.nlm.nih.gov/22962927.Fashner U., Ericson K., Werner S. Treatment of the Common Cold in Children and Adults. Am Fam Physician. 2012;86(2):153–159. Available at: https://pubmed.ncbi.nlm.nih.gov/22962927.Llir C. Acute bronchitis: aetiology and treatment. Eur Respir Monogr. 2013;60:1–17. doi: 10.1183/1025448x.10016912.Llir C. Acute bronchitis: aetiology and treatment. Eur Respir Monogr. 2013;60:1–17. doi: 10.1183/1025448x.10016912.Рязанцев С.В., Карнеева О.В., Гаращенко Т.И., Гуров А.В., Свистушкин В.М., Сапова К.И. и др. Острый синусит: клинические рекомендации. 2016. Режим доступа: http://www.nmaoru.org/files/KR313%20Ostryj%20sinusit.pdf.Ryazantsev S.V., Karneeva O.V., Garashchenko T.I., Gurov A.V.,Svistushkin V.M., Sapova K.I. Acute sinusitis: clinical guidelines. 2016. (In Russ.) Available at: http://www.nmaoru.org/files/KR313%20Ostryj%20sinusit.pdf.

The authors declare that there are no conflicts of interest present.